Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free PLX Stock Alerts

Protalix BioTherapeutics (PLX) Financials

Protalix BioTherapeutics logo
$2.32 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$2.31 -0.01 (-0.26%)
As of 07/2/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Protalix BioTherapeutics

Annual Income Statements for Protalix BioTherapeutics

This table shows Protalix BioTherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 58 -29 -83 -26 -18 -6.52 -28 -15 8.31 2.93 -6.60
Consolidated Net Income / (Loss)		 58 -29 -83 -26 -18 -6.52 -28 -15 8.31 2.93 -6.60
Net Income / (Loss) Continuing Operations		 -27 -29 -83 -26 -18 -6.52 -28 -15 8.31 2.93 -6.60
Total Pre-Tax Income 		-27 -29 -83 -26 -18 -6.52 -28 -14 8.57 4.15 -5.61
Total Operating Income		 -24 -33 -35 -19 -11 2.71 -20 -13 10 3.92 -5.50
Total Gross Profit		 3.63 0.80 5.85 -9.30 44 52 22 28 43 29 26
Total Revenue		 4.36 9.20 21 0.00 55 63 38 48 65 53 53
Operating Revenue		 4.36 9.20 21 - 55 63 38 48 65 53 53
Total Cost of Revenue		 0.73 8.40 15 9.30 11 11 16 20 23 24 27
Operating Cost of Revenue		 0.73 8.40 15 9.30 11 11 16 20 23 24 27
Total Operating Expenses		 27 34 40 10 55 49 42 41 32 25 31
Selling, General & Admin Expense		 7.28 9.36 12 11 9.90 11 13 12 15 12 12
Research & Development Expense		 25 30 32 33 45 38 30 29 17 13 20
Total Other Income / (Expense), net		 -3.61 3.99 -49 -7.15 -7.56 -9.23 -7.12 -1.38 -1.89 0.24 -0.11
Other Income / (Expense), net		 -3.61 -10 -48 -7.15 -7.56 -9.23 -7.12 -1.38 -1.89 0.24 -0.11
Income Tax Expense		 - - - - - 0.00 0.00 0.53 0.25 1.22 1.00
Basic Earnings per Share		 $0.61 ($0.29) ($6.37) ($1.80) ($1.23) ($0.22) ($0.62) ($0.31) $0.12 $0.04 ($0.08)
Weighted Average Basic Shares Outstanding		 94.92M 101.39M 13.11M 14.71M 14.84M 29.15M 44.14M 48.47M 67.51M 72.53M 78.55M
Diluted Earnings per Share		 $0.61 ($0.29) ($6.37) ($1.80) ($1.23) ($0.22) ($0.62) ($0.31) $0.09 $0.04 ($0.08)
Weighted Average Diluted Shares Outstanding		 94.92M 101.39M 13.11M 14.71M 14.84M 29.15M 44.14M 48.47M 82.42M 81.06M 78.55M
Weighted Average Basic & Diluted Shares Outstanding		 94.92M 101.39M 13.11M 14.71M 14.84M 29.15M 46.32M 57.35M 73.05M 78.03M 80.57M

Quarterly Income Statements for Protalix BioTherapeutics

This table shows Protalix BioTherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.85 -6.04 -4.60 -2.20 3.24 6.49 -3.62 0.16 2.36 -5.50 18
Consolidated Net Income / (Loss)		 -1.85 -6.04 -4.60 -2.20 3.24 6.49 -3.62 0.16 2.36 -5.50 18
Net Income / (Loss) Continuing Operations		 -1.85 -6.04 -4.60 -2.20 3.24 6.49 -3.62 0.16 2.36 -5.50 18
Total Pre-Tax Income 		-1.72 -6.43 -4.73 -2.27 3.84 7.32 -3.73 0.66 2.24 -4.78 21
Total Operating Income		 -1.89 -5.62 -4.86 -2.43 3.99 7.21 -4.15 1.17 2.13 -4.66 21
Total Gross Profit		 5.45 1.63 1.15 4.02 9.58 14 1.93 9.79 9.53 4.50 30
Total Revenue		 10 10 3.75 13 18 18 10 16 18 9.12 34
Operating Revenue		 10 10 3.75 13 18 18 10 16 18 9.12 34
Total Cost of Revenue		 4.89 8.86 2.60 9.46 8.38 3.89 8.18 5.87 8.32 4.62 4.13
Operating Cost of Revenue		 4.89 8.86 2.60 9.46 8.38 3.89 8.18 5.87 8.32 4.62 4.13
Total Operating Expenses		 7.34 7.25 6.00 6.45 5.59 7.12 6.08 8.62 7.40 9.16 8.48
Selling, General & Admin Expense		 3.67 4.14 3.12 3.48 2.60 3.00 2.60 2.62 2.93 3.53 3.05
Research & Development Expense		 3.67 3.10 2.89 2.96 3.00 4.12 3.48 5.99 4.47 5.64 5.43
Total Other Income / (Expense), net		 0.17 -0.81 0.12 0.16 -0.15 0.11 0.41 -0.51 0.11 -0.12 -0.01
Other Income / (Expense), net		 0.17 -0.81 0.12 0.16 -0.15 0.11 0.41 -0.51 0.11 -0.12 -0.01
Income Tax Expense		 0.13 -0.38 -0.14 -0.07 0.61 0.82 -0.11 0.50 -0.12 0.73 2.82
Basic Earnings per Share		 ($0.03) ($0.09) ($0.06) ($0.03) $0.04 $0.09 ($0.05) $0.00 $0.03 ($0.06) $0.23
Weighted Average Basic Shares Outstanding		 72.28M 67.51M 73.04M 73.31M 73.55M 72.53M 76.61M 78.66M 79.28M 78.55M 79.85M
Diluted Earnings per Share		 ($0.04) ($0.03) ($0.06) ($0.03) $0.03 $0.10 ($0.05) $0.00 $0.03 ($0.06) $0.22
Weighted Average Diluted Shares Outstanding		 83.78M 82.42M 73.04M 73.31M 81.22M 81.06M 76.61M 81.27M 80.81M 78.55M 83.05M
Weighted Average Basic & Diluted Shares Outstanding		 72.95M 73.05M 73.32M 73.54M 73.63M 78.03M 79.61M 79.73M 80.42M 80.57M 80.57M

Annual Cash Flow Statements for Protalix BioTherapeutics

This table details how cash moves in and out of Protalix BioTherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 22 -13 -12 -13 -20 0.47 21 -22 6.52 -3.87 -5.08
Net Cash From Operating Activities		 -24 -32 -9.99 -7.74 -19 -26 -10 -25 -1.32 8.67 -12
Net Cash From Continuing Operating Activities		 -26 -32 -9.99 -7.74 -19 -26 -10 -25 -1.32 8.67 -12
Net Income / (Loss) Continuing Operations		 -27 -29 -83 -26 -18 -6.52 -28 -15 8.31 2.93 -6.60
Consolidated Net Income / (Loss)		 58 -29 -83 -26 -18 -6.52 -28 -15 8.31 2.93 -6.60
Depreciation Expense		 2.37 1.98 1.92 1.67 1.62 1.30 1.12 1.09 1.19 1.30 1.47
Amortization Expense		 0.45 0.57 2.33 2.60 2.99 3.47 2.67 0.30 0.27 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 2.00 -6.58 42 0.92 1.04 2.87 3.85 0.55 2.56 3.39 2.89
Changes in Operating Assets and Liabilities, net		 -3.30 1.12 27 14 -6.73 -27 9.66 -12 -14 1.05 -9.74
Net Cash From Investing Activities		 39 -0.97 -1.12 -0.59 -0.88 -20 19 -5.04 -17 4.22 -2.37
Net Cash From Continuing Investing Activities		 -0.51 -0.97 -1.12 -0.59 -0.88 -20 19 -5.04 -17 4.22 -2.37
Purchase of Property, Plant & Equipment		 -0.46 -0.85 -0.97 -0.69 -0.63 -0.66 -1.46 -0.63 -1.15 -1.28 -1.64
Sale of Property, Plant & Equipment		 0.00 0.02 0.00 - 0.00 0.00 0.05 0.00 0.00 0.00 0.00
Other Investing Activities, net		 -0.05 -0.14 -0.15 0.03 0.00 -19 20 -4.41 -16 5.50 -0.73
Net Cash From Financing Activities		 6.64 20 -1.42 -4.75 0.00 46 12 8.24 25 -17 9.33
Net Cash From Continuing Financing Activities		 6.64 20 -1.42 -4.75 0.00 46 12 8.24 25 -17 9.33
Repayment of Debt		 - - -11 -4.75 0.00 -0.22 -34 0.00 0.00 -20 0.00
Issuance of Common Equity		 6.10 - - 0.00 0.00 46 46 8.24 24 3.63 6.81
Other Financing Activities, net		 0.53 0.01 - 0.00 0.00 0.47 0.00 0.00 0.71 0.00 2.51
Effect of Exchange Rate Changes		 -0.13 0.28 0.41 -0.27 0.23 0.06 0.01 -0.08 -0.11 0.03 -0.05
Cash Interest Paid		 3.11 3.66 4.85 4.59 4.34 4.34 3.41 2.20 2.74 1.53 0.00
Cash Interest Received		 - - - 0.40 0.41 0.44 0.38 0.09 0.36 1.49 0.65
Cash Income Taxes Paid		 - - - - - - - 0.00 0.00 0.39 1.18

Quarterly Cash Flow Statements for Protalix BioTherapeutics

This table details how cash moves in and out of Protalix BioTherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -28 3.23 3.58 -3.81 4.01 -7.65 -0.30 -1.56 -4.25 1.03 26
Net Cash From Operating Activities		 -6.89 3.60 4.19 -3.61 4.11 3.99 -5.06 -5.23 -3.73 2.03 22
Net Cash From Continuing Operating Activities		 -6.89 3.60 4.19 -3.61 4.11 3.99 -5.06 -5.23 -3.73 2.03 22
Net Income / (Loss) Continuing Operations		 -1.85 -6.04 -4.60 -2.20 3.24 6.49 -3.62 0.16 2.36 -5.50 18
Consolidated Net Income / (Loss)		 -1.85 -6.04 -4.60 -2.20 3.24 6.49 -3.62 0.16 2.36 -5.50 18
Depreciation Expense		 0.31 0.31 0.32 0.32 0.33 0.33 0.35 0.36 0.37 0.39 0.40
Non-Cash Adjustments To Reconcile Net Income		 0.64 1.49 0.53 0.50 1.76 0.59 0.15 0.89 0.59 1.26 0.75
Changes in Operating Assets and Liabilities, net		 -6.04 7.77 7.93 -2.23 -1.22 -3.43 -1.94 -6.65 -7.05 5.89 2.55
Net Cash From Investing Activities		 -21 -0.34 -0.61 -0.18 20 -15 -0.31 -0.44 -0.50 -1.11 4.22
Net Cash From Continuing Investing Activities		 -21 -0.34 -0.61 -0.18 20 -15 -0.31 -0.44 -0.50 -1.11 4.22
Purchase of Property, Plant & Equipment		 -0.45 -0.25 -0.60 -0.17 -0.09 -0.43 -0.31 -0.43 -0.50 -0.40 -0.76
Other Investing Activities, net		 -20 -0.09 -0.01 -0.01 20 -15 -0.01 -0.01 -0.01 -0.71 4.98
Net Cash From Financing Activities		 - - 0.00 - -20 3.63 5.08 4.10 - 0.15 0.15
Net Cash From Continuing Financing Activities		 - - 0.00 - -20 3.63 5.08 4.10 - 0.15 0.15
Issuance of Common Equity		 - - 0.00 - - 3.63 2.86 3.95 - - 0.00
Other Financing Activities, net		 - - 0.00 - - - 2.22 0.15 - 0.15 0.15
Effect of Exchange Rate Changes		 -0.01 -0.03 -0.01 -0.02 -0.00 0.05 -0.01 0.00 -0.01 -0.03 -0.08
Cash Interest Received		 0.23 0.05 0.03 0.02 1.43 0.01 0.17 0.05 0.04 0.39 0.69
Cash Income Taxes Paid		 - - - - - - 0.00 - - 0.00 2.50

Annual Balance Sheets for Protalix BioTherapeutics

This table presents Protalix BioTherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 97 82 72 61 45 68 74 56 84 73 82
Total Current Assets		 86 72 63 53 32 56 62 45 70 60 67
Cash & Equivalents		 76 63 51 38 18 18 39 17 24 20 15
Restricted Cash		 - - - - - - - - - 0.00 0.70
Accounts Receivable		 - 0.69 1.72 4.73 4.70 2.00 3.44 4.59 5.27 2.91 8.84
Inventories, net		 5.77 5.25 7.83 8.57 8.16 13 18 17 19 21 26
Other Current Assets		 1.67 2.65 1.93 1.88 1.83 22 1.29 6.38 22 16 17
Plant, Property, & Equipment, net		 9.74 8.70 7.68 6.39 5.27 4.85 4.96 4.55 4.97 4.59 4.88
Total Noncurrent Assets		 1.63 1.68 1.89 1.76 7.64 7.37 7.04 6.35 9.53 8.75 11
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - 0.00 3.09 2.86 2.52
Employee Benefit Assets		 1.63 1.68 1.89 1.76 1.96 1.80 2.08 1.27 0.53 0.46 0.58
Other Noncurrent Operating Assets		 - - - 0.00 5.68 5.57 4.96 5.09 5.91 5.43 7.70
Total Liabilities & Shareholders' Equity		 97 82 72 61 45 68 74 56 84 73 82
Total Liabilities		 86 92 102 114 116 95 80 66 51 30 34
Total Current Liabilities		 11 66 23 25 40 86 33 32 46 26 27
Accounts Payable		 9.16 12 17 15 18 21 23 18 4.32 4.53 5.26
Other Current Liabilities		 - - - 9.87 17 6.81 1.21 14 21 21 21
Total Noncurrent Liabilities		 75 26 79 89 76 8.50 47 34 5.34 4.59 7.60
Noncurrent Employee Benefit Liabilities		 2.30 2.35 2.59 2.37 2.57 2.26 2.47 1.64 0.71 0.56 0.66
Other Noncurrent Operating Liabilities		 - 4.30 30 38 17 1.77 4.38 - - 4.03 6.94
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 11 -9.96 -29 -53 -70 -27 -6.04 -11 34 43 48
Total Preferred & Common Equity		 11 -9.96 -29 -53 -70 -27 -6.04 -11 34 43 48
Total Common Equity		 11 -9.96 -29 -53 -70 -27 -6.04 -11 34 43 48
Common Stock		 194 203 267 270 271 320 369 379 415 422 48

Quarterly Balance Sheets for Protalix BioTherapeutics

This table presents Protalix BioTherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 88 90 92 62 74 78 82 102
Total Current Assets		 73 75 77 48 61 65 67 86
Cash & Equivalents		 20 27 23 27 19 18 14 41
Restricted Cash		 - - - - - - - 0.71
Accounts Receivable		 8.94 3.76 10 2.20 4.68 9.44 14 2.94
Inventories, net		 22 22 21 17 20 21 21 30
Other Current Assets		 22 22 23 1.05 17 17 17 11
Plant, Property, & Equipment, net		 4.68 4.78 4.61 4.65 4.73 4.75 4.72 5.15
Total Noncurrent Assets		 10 9.64 9.56 9.06 8.65 8.26 11 11
Noncurrent Deferred & Refundable Income Taxes		 3.09 3.23 3.30 2.86 2.97 2.74 2.68 2.45
Employee Benefit Assets		 1.26 0.53 0.54 0.56 0.46 0.52 0.55 0.59
Other Noncurrent Operating Assets		 5.92 5.88 5.73 5.65 5.23 5.00 7.81 7.79
Total Liabilities & Shareholders' Equity		 88 90 92 62 74 78 82 102
Total Liabilities		 49 60 63 29 29 29 29 35
Total Current Liabilities		 43 55 58 24 24 24 22 27
Accounts Payable		 22 22 23 23 4.12 6.69 5.38 4.29
Other Current Liabilities		 1.31 12 14 1.51 20 17 17 23
Total Noncurrent Liabilities		 5.96 5.21 4.99 4.91 4.36 4.49 7.41 7.72
Noncurrent Employee Benefit Liabilities		 1.46 0.71 0.71 0.73 0.55 0.62 0.63 0.67
Other Noncurrent Operating Liabilities		 - 4.50 - - 3.81 - - 7.05
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 38 30 29 32 45 50 53 67
Total Preferred & Common Equity		 38 30 29 32 45 50 53 67
Total Common Equity		 38 30 29 32 45 50 53 67
Common Stock		 38 30 29 32 45 50 53 67

Annual Metrics And Ratios for Protalix BioTherapeutics

This table displays calculated financial ratios and metrics derived from Protalix BioTherapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 99,800,397.00 99,930,402.00 139,727,673.00 296,749,842.00 148,382,299.00 33,336,709.00 45,556,647.00 50,665,598.00 72,952,124.00 - 80,421,181.00
DEI Adjusted Shares Outstanding		 9,980,040.00 9,993,040.00 13,972,767.00 29,674,984.00 14,838,230.00 33,336,709.00 45,556,647.00 50,665,598.00 72,952,124.00 - 80,421,181.00
DEI Earnings Per Adjusted Shares Outstanding		 5.82 -2.94 -5.97 -0.89 -1.23 -0.20 -0.61 -0.29 0.11 - -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 23.87% 110.79% 129.13% -100.00% 0.00% 15.00% -39.03% 24.22% 37.48% -18.47% -1.23%
EBITDA Growth		 17.66% -66.30% -91.36% 71.51% 38.39% 87.19% -1,258.71% 45.31% 177.04% -45.55% -175.91%
EBIT Growth		 18.07% -58.49% -89.91% 67.78% 30.92% 64.31% -322.84% 47.80% 159.50% -51.51% -235.00%
NOPAT Growth		 17.12% -40.11% -4.08% 44.06% 44.49% 125.29% -855.06% 36.40% 211.42% -72.76% -239.25%
Net Income Growth		 293.82% -150.60% -184.15% 68.29% 30.92% 64.31% -322.84% 45.88% 155.68% -64.73% -325.24%
EPS Growth		 290.63% -147.54% -184.15% 68.29% 31.67% 82.11% -181.82% 50.00% 129.03% -55.56% -300.00%
Operating Cash Flow Growth		 17.07% -32.18% 68.86% 22.53% -150.04% -34.86% 60.60% -143.07% 94.73% 758.12% -238.26%
Free Cash Flow Firm Growth		 73.85% 4.72% 124.84% -81.74% -2,923.95% -101.44% 146.45% -250.57% 35.00% 170.42% -193.81%
Invested Capital Growth		 29.24% -100.38% -123,517.39% -50.26% 33.69% 162.40% -196.92% 126.88% 655.85% -32.63% 40.07%
Revenue Q/Q Growth		 174.10% 29.24% 11.80% -100.00% 319.20% 59.17% -45.94% 0.14% 2.94% 16.93% -14.71%
EBITDA Q/Q Growth		 11.21% -24.70% 6.09% 22.85% 29.90% 6.06% -49.85% 20.93% -24.17% 166.19% -152.47%
EBIT Q/Q Growth		 10.65% -23.11% 5.42% 19.83% 23.85% 1.60% -34.43% 19.36% -27.30% 143.33% -186.49%
NOPAT Q/Q Growth		 10.36% -3.17% -2.56% 23.44% 35.40% 30.85% -71.70% 19.79% -17.05% 144.34% -172.69%
Net Income Q/Q Growth		 348.74% -163.62% -14.68% 22.93% 23.85% 1.60% -34.43% 16.39% -21.70% 130.52% -222.43%
EPS Q/Q Growth		 256.41% -159.18% -14.68% 22.93% 24.07% -10.00% -37.78% 13.89% 125.00% 144.44% -200.00%
Operating Cash Flow Q/Q Growth		 4.02% -12.16% 71.38% -155.89% 1.61% -17.37% 19.32% 9.01% 82.48% 4.78% -19.55%
Free Cash Flow Firm Q/Q Growth		 25.69% 72.93% 119.35% -97.32% -32.65% 14.62% 252.31% -4,723.89% 1.65% -47.88% 58.00%
Invested Capital Q/Q Growth		 117.41% -100.40% -798.06% -0.55% 24.65% 13.93% -183.07% -53.52% -18.16% 154.79% -28.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 83.27% 8.71% 27.74% 0.00% 80.08% 82.71% 57.37% 58.87% 64.91% 54.46% 48.82%
EBITDA Margin		 -560.66% -442.31% -369.39% 0.00% -24.99% -2.78% -62.04% -27.31% 15.31% 10.22% -7.85%
Operating Margin		 -542.39% -360.51% -163.76% 0.00% -19.59% 4.31% -53.36% -27.32% 15.97% 7.34% -10.43%
EBIT Margin		 -625.16% -470.04% -389.58% 0.00% -33.42% -10.37% -71.92% -30.22% 13.08% 7.78% -10.63%
Profit (Net Income) Margin		 1,329.90% -319.22% -395.86% 0.00% -33.42% -10.37% -71.92% -31.33% 12.69% 5.49% -12.52%
Tax Burden Percent		 -212.73% 100.65% 100.00% 100.00% 100.00% 100.00% 100.00% 103.68% 97.03% 70.58% 117.76%
Interest Burden Percent		 100.00% 67.48% 101.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.97% 29.42% 0.00%
Return on Invested Capital (ROIC)		 -306.72% -765.13% 0.00% 0.00% 0.00% 0.00% -5,265.96% 0.00% 51.51% 9.49% -13.68%
ROIC Less NNEP Spread (ROIC-NNEP)		 -38.02% -1,003.91% 0.00% 0.00% 0.00% 0.00% -5,344.84% 0.00% 29.21% 7.69% 2.00%
Return on Net Nonoperating Assets (RNNOA)		 47.21% -5,646.44% 0.00% 0.00% 0.00% 0.00% 5,432.75% 0.00% 21.00% -1.85% -0.77%
Return on Equity (ROE)		 -259.51% -6,411.57% 423.40% 64.26% 29.67% 13.40% 166.79% 179.02% 72.50% 7.64% -14.44%
Cash Return on Invested Capital (CROIC)		 -332.23% 0.00% 0.00% 0.00% 0.00% -249.51% 0.00% -669.90% -101.76% 48.48% -47.06%
Operating Return on Assets (OROA)		 -31.07% -48.18% -106.32% 0.00% -34.31% -11.51% -38.96% -22.24% 12.22% 5.26% -7.20%
Return on Assets (ROA)		 66.10% -32.72% -108.04% 0.00% -34.31% -11.51% -38.96% -23.06% 11.86% 3.71% -8.48%
Return on Common Equity (ROCE)		 -259.51% -6,411.57% 423.40% 64.26% 29.67% 13.40% 166.79% 179.02% 72.50% 7.64% -14.44%
Return on Equity Simple (ROE_SIMPLE)		 533.77% 294.92% 283.26% 50.03% 25.99% 24.13% 456.96% 140.29% 0.00% 6.79% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -23 -24 -14 -7.50 1.90 -14 -9.11 10 2.76 -3.85
NOPAT Margin		 -379.67% -252.35% -114.63% 0.00% -13.72% 3.02% -37.35% -19.12% 15.50% 5.18% -7.30%
Net Nonoperating Expense Percent (NNEP)		 -268.70% 238.78% 1,081.82% 231.45% 41.32% 19.42% 78.88% 280.55% 22.30% 1.81% -15.67%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -41.95% 17.37% 6.40% -7.98%
Cost of Revenue to Revenue		 16.73% 91.29% 72.26% 0.00% 19.92% 17.29% 42.63% 41.13% 35.09% 45.54% 51.18%
SG&A Expenses to Revenue		 166.80% 101.71% 54.70% 0.00% 18.10% 17.72% 33.19% 24.58% 22.84% 22.83% 22.15%
R&D to Revenue		 570.33% 330.60% 152.62% 0.00% 81.58% 60.68% 77.53% 61.61% 26.10% 24.29% 37.10%
Operating Expenses to Revenue		 625.66% 369.21% 191.50% 0.00% 99.67% 78.40% 110.72% 86.19% 48.94% 47.12% 59.25%
Earnings before Interest and Taxes (EBIT)		 -27 -43 -82 -26 -18 -6.52 -28 -14 8.57 4.15 -5.61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -41 -78 -22 -14 -1.75 -24 -13 10 5.46 -4.14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.87 3.20 3.00
Price to Tangible Book Value (P/TBV)		 9.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.87 3.20 3.00
Price to Revenue (P/Rev)		 23.33 4.83 4.38 0.00 0.89 1.92 0.99 1.46 1.98 2.59 2.74
Price to Earnings (P/E)		 1.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.62 47.21 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 57.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.40% 2.12% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 16.01 0.00 0.00 0.00 0.00 9.37 0.00 18.38 3.77 5.06 3.94
Enterprise Value to Revenue (EV/Rev)		 22.35 5.91 4.43 0.00 1.66 2.63 0.70 1.78 2.00 2.22 2.45
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.08 21.74 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.30 28.57 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 87.36 0.00 0.00 12.92 42.92 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.68 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 21.99 72.61 0.00 0.00 1.31 0.00 0.00 8.40 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 6.63 -7.35 -1.77 -0.91 -0.85 -2.33 -4.62 -3.04 0.74 0.00 0.00
Long-Term Debt to Equity		 6.63 -1.94 -1.57 -0.91 -0.79 -0.17 -4.62 -3.04 0.14 0.00 0.00
Financial Leverage		 -1.24 5.62 -0.28 -0.14 -0.42 -0.89 -1.02 -0.25 0.72 -0.24 -0.38
Leverage Ratio		 -3.93 195.96 -3.92 -1.62 -0.86 -1.16 -4.28 -7.76 6.12 2.06 1.70
Compound Leverage Factor		 -3.93 132.23 -3.98 -1.62 -0.86 -1.16 -4.28 -7.76 6.12 2.06 1.70
Debt to Total Capital		 86.90% 115.74% 229.59% -975.91% -567.45% 175.22% 127.62% 149.00% 42.56% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 85.16% 26.05% 0.00% -40.82% 162.79% 0.00% 0.00% 34.65% 0.00% 0.00%
Long-Term Debt to Total Capital		 86.90% 30.58% 203.54% -975.91% -526.62% 12.43% 127.62% 149.00% 7.91% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 13.10% -15.74% -129.59% 1,075.91% 667.45% -75.22% -27.62% -49.00% 57.44% 100.00% 100.00%
Debt to EBITDA		 -2.95 -1.80 -0.67 -2.16 -4.37 -35.97 -1.17 -2.49 2.48 0.00 0.00
Net Debt to EBITDA		 0.17 -0.24 -0.01 -0.46 -3.07 -25.54 0.47 -1.17 0.12 0.00 0.00
Long-Term Debt to EBITDA		 -2.95 -0.48 -0.59 -2.16 -4.06 -2.55 -1.17 -2.49 0.46 0.00 0.00
Debt to NOPAT		 -4.35 -3.15 -2.16 -3.55 -7.97 33.20 -1.95 -3.55 2.45 0.00 0.00
Net Debt to NOPAT		 0.26 -0.43 -0.04 -0.75 -5.60 23.57 0.77 -1.67 0.12 0.00 0.00
Long-Term Debt to NOPAT		 -4.35 -0.83 -1.91 -3.55 -7.40 2.35 -1.95 -3.55 0.46 0.00 0.00
Altman Z-Score		 -1.89 -4.87 -7.99 -8.03 -10.59 -6.33 -7.09 -8.89 -3.34 -2.99 3.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.64 1.09 2.75 2.09 0.81 0.64 1.86 1.38 1.54 2.34 2.51
Quick Ratio		 6.80 0.97 2.32 1.68 0.56 0.23 1.28 0.67 0.63 0.88 0.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -17 4.25 0.78 -22 -44 20 -31 -20 14 -13
Operating Cash Flow to CapEx		 -5,267.68% -3,871.89% -1,032.44% -1,128.57% -3,087.40% -3,985.65% -731.51% -3,980.89% -114.71% 678.19% -732.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 3.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -7.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -8.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.10 0.27 0.00 1.03 1.11 0.54 0.74 0.93 0.68 0.68
Accounts Receivable Turnover		 0.00 0.00 17.46 0.00 11.60 18.78 14.09 11.87 13.29 13.05 8.98
Inventory Turnover		 0.16 1.53 2.33 1.13 1.30 1.02 1.05 1.13 1.28 1.21 1.15
Fixed Asset Turnover		 0.42 1.00 2.57 0.00 9.38 12.43 7.82 10.01 13.75 11.17 11.14
Accounts Payable Turnover		 0.07 0.81 1.08 0.58 0.64 0.55 0.73 0.94 2.05 5.49 5.51
Days Sales Outstanding (DSO)		 0.00 0.00 20.90 0.00 31.46 19.44 25.90 30.76 27.47 27.96 40.65
Days Inventory Outstanding (DIO)		 2,304.50 239.31 156.70 321.80 280.14 356.46 346.45 323.77 284.68 302.34 317.58
Days Payable Outstanding (DPO)		 4,950.25 449.10 339.50 634.02 567.60 663.78 497.48 387.06 178.30 66.44 66.20
Cash Conversion Cycle (CCC)		 -2,645.75 -209.79 -161.90 0.00 -256.00 -287.89 -125.13 -32.53 133.85 263.86 292.03
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.09 -0.02 -28 -43 -28 18 -17 4.61 35 23 33
Invested Capital Turnover		 0.81 3.03 -1.48 0.00 -1.54 -11.81 140.99 -7.60 3.32 1.83 1.87
Increase / (Decrease) in Invested Capital		 1.38 -6.11 -28 -14 14 46 -35 22 30 -11 9.40
Enterprise Value (EV)		 98 54 93 56 91 166 27 85 131 119 129
Market Capitalization		 102 44 92 46 49 121 38 69 130 138 145
Book Value per Share		 $0.11 ($0.10) ($0.21) ($0.36) ($0.47) ($0.81) ($0.13) ($0.21) $0.46 $0.59 $0.60
Tangible Book Value per Share		 $0.11 ($0.10) ($0.21) ($0.36) ($0.47) ($0.81) ($0.13) ($0.21) $0.46 $0.59 $0.60
Total Capital		 83 63 23 -4.92 -11 36 22 22 58 43 48
Total Debt		 72 73 52 48 60 63 28 32 25 0.00 0.00
Total Long-Term Debt		 72 19 46 48 55 4.47 28 32 4.62 0.00 0.00
Net Debt		 -4.28 9.93 1.03 10 42 45 -11 15 1.24 -20 -15
Capital Expenditures (CapEx)		 0.46 0.83 0.97 0.69 0.63 0.66 1.41 0.63 1.15 1.28 1.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.73 -3.75 -5.34 -10 -21 9.50 -10 -4.66 21 15 25
Debt-free Net Working Capital (DFNWC)		 75 60 46 28 -3.40 28 28 12 45 34 40
Net Working Capital (NWC)		 75 5.66 40 28 -7.70 -31 28 12 24 34 40
Net Nonoperating Expense (NNE)		 -75 6.15 59 13 11 8.42 13 5.82 1.84 -0.17 2.75
Net Nonoperating Obligations (NNO)		 -4.78 9.93 1.03 10 42 45 -11 15 1.24 -20 -15
Total Depreciation and Amortization (D&A)		 2.82 2.55 4.25 4.27 4.61 4.77 3.79 1.39 1.46 1.30 1.47
Debt-free, Cash-free Net Working Capital to Revenue		 -39.60% -40.81% -25.35% 0.00% -38.74% 15.10% -27.37% -9.78% 32.09% 27.52% 46.97%
Debt-free Net Working Capital to Revenue		 1,710.50% 647.10% 217.38% 0.00% -6.21% 44.14% 74.29% 26.14% 68.18% 64.53% 76.13%
Net Working Capital to Revenue		 1,710.50% 61.47% 189.29% 0.00% -14.07% -48.89% 74.29% 26.14% 37.26% 64.53% 76.13%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $6.10 ($2.90) ($6.50) ($1.80) ($1.23) ($0.22) ($0.62) ($0.31) $0.12 $0.04 ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 9.98M 12.41M 14.56M 14.84M 14.84M 45.38M 44.14M 48.47M 67.51M 72.53M 78.55M
Adjusted Diluted Earnings per Share		 $6.10 ($2.90) ($6.50) ($1.80) ($1.23) ($0.22) ($0.62) ($0.31) $0.09 $0.04 ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 9.98M 12.41M 14.56M 14.84M 14.84M 45.38M 44.14M 48.47M 82.42M 81.06M 78.55M
Adjusted Basic & Diluted Earnings per Share		 $6.10 ($2.90) ($6.50) ($1.80) ($1.23) ($0.22) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.49M 10.14M 13.11M 14.71M 14.84M 29.15M 46.32M 57.35M 73.05M 78.03M 80.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -23 -24 -14 -7.50 1.90 -14 -9.11 10 2.76 -3.85
Normalized NOPAT Margin		 -379.67% -252.35% -114.63% 0.00% -13.72% 3.02% -37.35% -19.12% 15.50% 5.18% -7.30%
Pre Tax Income Margin		 -625.16% -317.16% -395.86% 0.00% -33.42% -10.37% -71.92% -30.22% 13.08% 7.78% -10.63%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -61.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -18.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -62.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -18.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Protalix BioTherapeutics

This table displays calculated financial ratios and metrics derived from Protalix BioTherapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 71,580,762.00 72,952,124.00 73,052,124.00 73,316,084.00 73,542,674.00 - 78,032,585.00 79,607,115.00 79,732,115.00 80,421,181.00 80,571,642.00
DEI Adjusted Shares Outstanding		 71,580,762.00 72,952,124.00 73,052,124.00 73,316,084.00 73,542,674.00 - 78,032,585.00 79,607,115.00 79,732,115.00 80,421,181.00 80,571,642.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.03 -0.08 -0.06 -0.03 0.04 - -0.05 0.00 0.03 -0.07 0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -27.06% 21.69% -60.91% -61.59% 73.60% 73.74% 169.82% 16.21% -0.60% -49.93% 233.73%
EBITDA Growth		 57.90% -111.75% -71.23% -109.76% 408.12% 226.36% 23.24% 152.28% -37.42% -157.37% 736.30%
EBIT Growth		 51.81% -100.19% -61.21% -111.56% 323.56% 213.85% 21.15% 129.09% -41.74% -165.28% 666.48%
NOPAT Growth		 39.62% -125.05% -97.48% -108.45% 354.42% 262.80% 14.64% 117.12% -33.30% -150.95% 731.44%
Net Income Growth		 48.08% -61.60% -46.76% -111.39% 274.73% 207.45% 21.24% 107.44% -27.23% -184.76% 606.13%
EPS Growth		 42.86% 62.50% -20.00% -114.29% 175.00% 433.33% 16.67% 100.00% 0.00% -160.00% 540.00%
Operating Cash Flow Growth		 25.16% 237.69% 239.69% -172.59% 159.60% 11.02% -220.77% -44.96% -190.91% -49.14% 535.45%
Free Cash Flow Firm Growth		 -497.94% -45.33% -558.75% -210.36% 208.08% 152.02% 78.26% 72.33% -194.29% -171.29% 428.13%
Invested Capital Growth		 329.28% 655.85% 5,781.59% 172.94% -78.36% -32.63% 11.97% 20.08% 400.23% 40.07% -0.90%
Revenue Q/Q Growth		 -70.51% 1.36% -64.26% 259.50% 33.29% 1.44% -44.49% 54.83% 14.01% -48.90% 269.98%
EBITDA Q/Q Growth		 -106.77% -347.12% 27.14% 55.72% 313.62% 83.37% -144.26% 130.15% 155.73% -268.10% 590.89%
EBIT Q/Q Growth		 -108.75% -273.82% 26.35% 52.00% 269.15% 90.37% -151.01% 117.71% 238.73% -313.31% 542.65%
NOPAT Q/Q Growth		 -106.57% -197.56% 13.52% 50.02% 297.81% 90.41% -145.34% 110.02% 670.82% -245.47% 661.90%
Net Income Q/Q Growth		 -109.58% -226.35% 23.97% 52.06% 246.89% 100.68% -155.73% 104.53% 1,335.98% -333.72% 432.79%
EPS Q/Q Growth		 -119.05% 25.00% -100.00% 50.00% 200.00% 233.33% -150.00% 100.00% 0.00% -300.00% 466.67%
Operating Cash Flow Q/Q Growth		 -238.51% 152.19% 16.50% -186.20% 213.71% -2.78% -226.74% -3.46% 28.68% 154.39% 984.98%
Free Cash Flow Firm Q/Q Growth		 -281.56% -0.55% 23.81% 20.65% 277.81% -51.61% -131.85% -0.99% -505.85% 63.41% 246.59%
Invested Capital Q/Q Growth		 288.46% -18.16% -33.93% 29.95% -69.20% 154.79% 9.80% 39.36% 28.30% -28.65% -22.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 52.70% 15.54% 30.58% 29.82% 53.37% 78.67% 19.11% 62.51% 53.37% 49.36% 87.77%
EBITDA Margin		 -13.09% -57.73% -117.69% -14.49% 23.23% 41.99% -33.48% 6.52% 14.63% -48.11% 63.84%
Operating Margin		 -18.24% -53.55% -129.56% -18.01% 22.22% 39.57% -40.99% 7.49% 11.94% -51.06% 62.65%
EBIT Margin		 -16.62% -61.28% -126.28% -16.86% 21.40% 40.16% -36.90% 4.22% 12.54% -52.36% 62.64%
Profit (Net Income) Margin		 -17.90% -57.64% -122.60% -16.35% 18.02% 35.65% -35.79% 1.05% 13.19% -60.34% 54.27%
Tax Burden Percent		 107.74% 94.06% 97.08% 96.96% 84.21% 88.76% 96.97% 24.81% 105.18% 115.24% 86.64%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 15.80% 11.24% 0.00% 75.19% -5.18% 0.00% 13.36%
Return on Invested Capital (ROIC)		 -30.98% -124.58% -462.65% -23.50% 33.03% 64.39% -70.35% 3.50% 28.11% -66.97% 161.76%
ROIC Less NNEP Spread (ROIC-NNEP)		 -35.12% -150.22% -430.36% -19.73% 34.35% 63.36% -64.88% 5.49% 27.36% -54.21% 161.77%
Return on Net Nonoperating Assets (RNNOA)		 -33.77% -107.99% 103.50% 7.81% -9.21% -15.29% 22.71% -0.89% -9.65% 20.83% -88.01%
Return on Equity (ROE)		 -64.75% -232.57% -359.15% -15.69% 23.83% 49.10% -47.64% 2.61% 18.46% -46.14% 73.75%
Cash Return on Invested Capital (CROIC)		 -77.76% -101.76% -123.56% -143.44% 104.74% 48.48% 3.10% 1.16% -114.18% -47.06% 62.35%
Operating Return on Assets (OROA)		 -14.66% -57.25% -96.34% -7.13% 13.11% 27.17% -26.94% 3.08% 10.79% -35.46% 54.30%
Return on Assets (ROA)		 -15.79% -53.84% -93.53% -6.91% 11.04% 24.12% -26.13% 0.76% 11.34% -40.86% 47.05%
Return on Common Equity (ROCE)		 -64.75% -232.57% -359.15% -15.69% 23.83% 49.10% -47.64% 2.61% 18.46% -46.14% 73.75%
Return on Equity Simple (ROE_SIMPLE)		 27.76% 0.00% 22.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.32 -3.93 -3.40 -1.70 3.36 6.40 -2.90 0.29 2.24 -3.26 18
NOPAT Margin		 -12.77% -37.48% -90.69% -12.61% 18.71% 35.12% -28.69% 1.86% 12.56% -35.74% 54.29%
Net Nonoperating Expense Percent (NNEP)		 4.13% 25.64% -32.29% -3.77% -1.32% 1.03% -5.47% -1.99% 0.75% -12.77% -0.01%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.73% -6.77% -3.19% 9.18% 14.81% -6.42% 0.54% 3.76% -6.76% 27.25%
Cost of Revenue to Revenue		 47.30% 84.46% 69.42% 70.18% 46.63% 21.33% 80.89% 37.49% 46.63% 50.64% 12.23%
SG&A Expenses to Revenue		 35.48% 39.51% 83.11% 25.86% 14.45% 16.46% 25.74% 16.76% 16.41% 38.65% 9.04%
R&D to Revenue		 35.47% 29.58% 77.03% 21.98% 16.69% 22.64% 34.36% 38.27% 25.02% 61.77% 16.08%
Operating Expenses to Revenue		 70.94% 69.09% 160.14% 47.83% 31.14% 39.10% 60.10% 55.03% 41.43% 100.43% 25.12%
Earnings before Interest and Taxes (EBIT)		 -1.72 -6.43 -4.73 -2.27 3.84 7.32 -3.73 0.66 2.24 -4.78 21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.35 -6.05 -4.41 -1.95 4.17 7.65 -3.39 1.02 2.61 -4.39 22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.11 3.87 3.09 3.00 2.31 3.20 4.42 2.36 3.35 3.00 2.60
Price to Tangible Book Value (P/TBV)		 3.11 3.87 3.09 3.00 2.31 3.20 4.42 2.36 3.35 3.00 2.60
Price to Revenue (P/Rev)		 1.87 1.98 1.54 2.25 1.64 2.59 3.34 1.90 2.86 2.74 2.29
Price to Earnings (P/E)		 11.19 15.62 13.44 0.00 0.00 47.21 51.12 18.78 32.82 0.00 11.40
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 8.93% 6.40% 7.44% 0.00% 0.00% 2.12% 1.96% 5.33% 3.05% 0.00% 8.77%
Enterprise Value to Invested Capital (EV/IC)		 2.89 3.77 3.71 2.91 5.63 5.06 7.00 2.89 3.70 3.94 5.22
Enterprise Value to Revenue (EV/Rev)		 1.93 2.00 1.43 2.29 1.13 2.22 3.02 1.68 2.75 2.45 1.74
Enterprise Value to EBITDA (EV/EBITDA)		 9.31 13.08 10.65 0.00 0.00 21.74 27.81 10.98 21.55 0.00 6.40
Enterprise Value to EBIT (EV/EBIT)		 10.45 15.30 12.60 0.00 0.00 28.57 34.98 12.83 26.24 0.00 6.91
Enterprise Value to NOPAT (EV/NOPAT)		 10.06 12.92 10.45 0.00 0.00 42.92 51.39 16.26 32.12 0.00 8.45
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 14.53 0.00 6.26 13.68 0.00 0.00 0.00 0.00 8.82
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 1.91 8.40 238.66 271.84 0.00 0.00 8.33
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.65 0.74 0.69 0.86 0.13 0.00 0.00 0.08 0.13 0.00 0.00
Long-Term Debt to Equity		 0.12 0.14 0.00 0.15 0.13 0.00 0.00 0.08 0.13 0.00 0.00
Financial Leverage		 0.96 0.72 -0.24 -0.40 -0.27 -0.24 -0.35 -0.16 -0.35 -0.38 -0.54
Leverage Ratio		 5.40 6.12 5.08 2.66 2.11 2.06 2.18 2.17 1.69 1.70 1.57
Compound Leverage Factor		 5.40 6.12 5.08 2.66 2.11 2.06 2.18 2.17 1.69 1.70 1.57
Debt to Total Capital		 39.23% 42.56% 40.67% 46.36% 11.41% 0.00% 0.00% 7.21% 11.36% 0.00% 0.00%
Short-Term Debt to Total Capital		 32.08% 34.65% 40.67% 38.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 7.15% 7.91% 0.00% 8.04% 11.41% 0.00% 0.00% 7.21% 11.36% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 60.77% 57.44% 59.33% 53.64% 88.59% 100.00% 100.00% 92.79% 88.64% 100.00% 100.00%
Debt to EBITDA		 1.87 2.48 2.55 -1.78 -0.50 0.00 0.00 0.41 0.86 0.00 0.00
Net Debt to EBITDA		 0.32 0.12 -0.85 -0.09 2.80 0.00 0.00 -1.48 -0.87 0.00 0.00
Long-Term Debt to EBITDA		 0.34 0.46 0.00 -0.31 -0.50 0.00 0.00 0.41 0.86 0.00 0.00
Debt to NOPAT		 2.02 2.45 2.50 -2.39 -0.67 0.00 0.00 0.61 1.28 0.00 0.00
Net Debt to NOPAT		 0.35 0.12 -0.83 -0.13 3.73 0.00 0.00 -2.20 -1.30 0.00 0.00
Long-Term Debt to NOPAT		 0.37 0.46 0.00 -0.41 -0.67 0.00 0.00 0.61 1.28 0.00 0.00
Altman Z-Score		 2.51 -3.92 1.69 1.41 2.95 -2.85 5.41 3.92 5.11 3.58 5.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.67 1.54 1.38 1.33 1.98 2.34 2.49 2.72 3.03 2.51 3.15
Quick Ratio		 0.68 0.63 0.56 0.58 1.22 0.88 0.99 1.13 1.28 0.89 1.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -34 -34 -26 -21 37 18 -5.65 -5.71 -35 -13 19
Operating Cash Flow to CapEx		 -1,540.94% 1,438.00% 700.33% -2,098.84% 4,718.39% 939.06% -1,652.94% -1,214.15% -749.40% 503.72% 2,894.22%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.88 0.93 0.76 0.42 0.61 0.68 0.73 0.73 0.86 0.68 0.87
Accounts Receivable Turnover		 7.24 13.29 23.56 5.37 8.21 13.05 14.17 6.33 7.44 8.98 20.06
Inventory Turnover		 0.91 1.28 1.06 1.28 1.51 1.21 1.43 1.26 1.37 1.15 0.92
Fixed Asset Turnover		 13.59 13.75 12.58 8.23 9.79 11.17 12.57 13.24 13.20 11.14 15.46
Accounts Payable Turnover		 0.82 2.05 1.11 1.14 1.31 5.49 2.30 1.75 1.87 5.51 5.46
Days Sales Outstanding (DSO)		 50.44 27.47 15.49 67.98 44.48 27.96 25.75 57.65 49.05 40.65 18.19
Days Inventory Outstanding (DIO)		 399.23 284.68 345.95 285.37 241.65 302.34 255.48 290.28 267.25 317.58 397.62
Days Payable Outstanding (DPO)		 445.82 178.30 328.45 320.04 277.69 66.44 158.94 208.75 195.20 66.20 66.87
Cash Conversion Cycle (CCC)		 3.85 133.85 32.99 33.32 8.44 263.86 122.29 139.18 121.10 292.03 348.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 43 35 23 30 9.20 23 26 36 46 33 26
Invested Capital Turnover		 2.43 3.32 5.10 1.86 1.77 1.83 2.45 1.88 2.24 1.87 2.98
Increase / (Decrease) in Invested Capital		 33 30 23 19 -33 -11 2.75 6.00 37 9.40 -0.23
Enterprise Value (EV)		 123 131 85 87 52 119 180 104 170 129 133
Market Capitalization		 119 130 92 86 75 138 200 118 177 145 175
Book Value per Share		 $0.53 $0.46 $0.41 $0.39 $0.44 $0.59 $0.58 $0.63 $0.66 $0.60 $0.83
Tangible Book Value per Share		 $0.53 $0.46 $0.41 $0.39 $0.44 $0.59 $0.58 $0.63 $0.66 $0.60 $0.83
Total Capital		 63 58 50 53 37 43 45 54 60 48 67
Total Debt		 25 25 20 25 4.18 0.00 0.00 3.88 6.78 0.00 0.00
Total Long-Term Debt		 4.50 4.62 0.00 4.28 4.18 0.00 0.00 3.88 6.78 0.00 0.00
Net Debt		 4.29 1.24 -6.79 1.30 -23 -20 -19 -14 -6.87 -15 -42
Capital Expenditures (CapEx)		 0.45 0.25 0.60 0.17 0.09 0.43 0.31 0.43 0.50 0.40 0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 29 21 14 16 -3.78 15 17 23 31 25 17
Debt-free Net Working Capital (DFNWC)		 49 45 41 40 24 34 36 41 45 40 59
Net Working Capital (NWC)		 29 24 21 19 24 34 36 41 45 40 59
Net Nonoperating Expense (NNE)		 0.53 2.11 1.20 0.50 0.12 -0.09 0.72 0.13 -0.11 2.24 0.00
Net Nonoperating Obligations (NNO)		 4.29 1.24 -6.79 1.30 -23 -20 -19 -14 -6.87 -15 -42
Total Depreciation and Amortization (D&A)		 0.37 0.37 0.32 0.32 0.33 0.33 0.35 0.36 0.37 0.39 0.40
Debt-free, Cash-free Net Working Capital to Revenue		 45.65% 32.09% 23.11% 43.14% -8.27% 27.52% 28.00% 37.93% 49.98% 46.97% 22.59%
Debt-free Net Working Capital to Revenue		 77.72% 68.18% 68.72% 104.63% 51.75% 64.53% 60.56% 66.82% 72.05% 76.13% 77.20%
Net Working Capital to Revenue		 45.99% 37.26% 34.49% 50.97% 51.75% 64.53% 60.56% 66.82% 72.05% 76.13% 77.20%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) ($0.09) ($0.06) ($0.03) $0.04 $0.09 ($0.05) $0.00 $0.03 ($0.06) $0.23
Adjusted Weighted Average Basic Shares Outstanding		 72.28M 67.51M 73.04M 73.31M 73.55M 72.53M 76.61M 78.66M 79.28M 78.55M 79.85M
Adjusted Diluted Earnings per Share		 ($0.04) ($0.03) ($0.06) ($0.03) $0.03 $0.10 ($0.05) $0.00 $0.03 ($0.06) $0.22
Adjusted Weighted Average Diluted Shares Outstanding		 83.78M 82.42M 73.04M 73.31M 81.22M 81.06M 76.61M 81.27M 80.81M 78.55M 83.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 72.95M 73.05M 73.32M 73.54M 73.63M 78.03M 79.61M 79.73M 80.42M 80.57M 80.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.32 -3.93 -3.40 -1.70 3.36 6.40 -2.90 0.82 1.49 -3.26 18
Normalized NOPAT Margin		 -12.77% -37.48% -90.69% -12.61% 18.71% 35.12% -28.69% 5.24% 8.36% -35.74% 54.29%
Pre Tax Income Margin		 -16.62% -61.28% -126.28% -16.86% 21.40% 40.16% -36.90% 4.22% 12.54% -52.36% 62.64%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Protalix BioTherapeutics (NYSE:PLX) delivered a sharp turnaround in Q1 2026, with revenue and profitability jumping significantly from the prior quarter and year-ago period. The company also finished the quarter with a much stronger cash position, helped by robust operating cash flow and a large positive swing in working capital.

  • Revenue surged to $33.8 million in Q1 2026, up from $9.1 million in Q4 2025 and $10.1 million in Q1 2025, showing a meaningful acceleration in the top line.
  • Net income reached $18.3 million, a major improvement from a $5.5 million loss in Q4 2025 and a $3.6 million loss in Q1 2025.
  • Operating income improved to $21.1 million, compared with an operating loss in the prior quarter and a loss a year ago, indicating much better core business performance.
  • Gross profit expanded to $29.6 million, with gross margin holding at a strong level as cost of revenue remained relatively low versus sales.
  • Operating cash flow was $22.0 million in Q1 2026, reversing a negative operating cash flow result in Q1 2025 and highlighting improved cash generation.
  • Cash and equivalents rose to $41.0 million at March 31, 2026, up from $13.6 million at the end of Q3 2025, giving the company more liquidity.
  • Shareholders’ equity increased to $67.2 million, up from $52.9 million in Q3 2025, reflecting a healthier balance sheet.
  • The company generated positive investing and financing cash support, which helped lift cash despite normal operating and tax payments.
  • Accounts receivable and inventories remain sizable, which is common for a biotech/commercial-stage company but still worth watching for working-capital efficiency.
  • Other current liabilities remain elevated at $23.1 million, which could pressure liquidity if revenue normalizes or working capital reverses.

Looking at the longer trend, PLX has been volatile. The business posted losses in early 2025 and much of 2024, but the latest quarter stands out as a clear improvement. Revenue in Q1 2026 was more than triple the level of the prior quarter, and the company moved from burning cash to producing meaningful operating cash flow.

The balance sheet also looks stronger than it did a year ago. Total assets rose to $102.3 million, while total liabilities were $35.1 million, leaving the company with a healthier equity cushion than in prior periods. That said, investors should keep an eye on quarterly consistency, since the historical numbers show that PLX can swing sharply from profit to loss.

Bottom line: Protalix BioTherapeutics entered 2026 with improved momentum, stronger liquidity, and a much better income statement than in recent quarters. The key question for investors is whether this level of revenue and profitability is sustainable.

07/05/26 07:47 AM ETAI Generated. May Contain Errors.

Protalix BioTherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Protalix BioTherapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Protalix BioTherapeutics' net income appears to be on a downward trend, with a most recent value of -$6.60 million in 2025, falling from $58.04 million in 2015. The previous period was $2.93 million in 2024. See Protalix BioTherapeutics' forecast for analyst expectations on what's next for the company.

Protalix BioTherapeutics' total operating income in 2025 was -$5.50 million, based on the following breakdown:
  • Total Gross Profit: $25.75 million
  • Total Operating Expenses: $31.25 million

Over the last 10 years, Protalix BioTherapeutics' total revenue changed from $4.36 million in 2015 to $52.74 million in 2025, a change of 1,108.6%.

Protalix BioTherapeutics' total liabilities were at $34.12 million at the end of 2025, a 12.9% increase from 2024, and a 60.5% decrease since 2015.

In the past 10 years, Protalix BioTherapeutics' cash and equivalents has ranged from $14.68 million in 2025 to $76.37 million in 2015, and is currently $14.68 million as of their latest financial filing in 2025.

Over the last 10 years, Protalix BioTherapeutics' book value per share changed from 0.11 in 2015 to 0.60 in 2025, a change of 450.7%.


Related Companies

Financial statements for NYSE:PLX last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel